BIFIDOBACTERIUM LACTIS Bl-04®

Learn more about our premium strain for immune health
doctor-resp
Clinical Trials
Community Based Clinical Study

AIM OF THE STUDY

This study was designed to understand if daily intake of a formulation containing Bifidobacterium lactis Bl-04® would have a positive impact in the prevention of upper respiratory tract (URT) illness episodes

PRODUCT FORMULA

Bifidobacterium lactis Bl-04® 2 Billion CFU

STUDY DESIGN

5 month, double-blind, placebo-controlled study
Evaluation of symptoms & physical activity via Web-based questionnaire.

SUBJECTS

310 healthy physically active-adults, average age of 35 years

UNIVERSITY

Griffith Health Institute, Griffith University & Australian Institute of sport, Australia

PUBLICATION

West et al. 2014 Clinical Nutrition

home-office-07-1
home-office-07-1
Challenge study with rhinovirus – the causative agent of common cold

AIM OF THE STUDY

To study the effect of Bifidobacterium lactis Bl-04® on immune response and rhinovirus load during rhinovirus infection that causes common cold.

PRODUCT FORMULA

Bifidobacterium lactis Bl-04® 2 Billion CFU

STUDY DESIGN

Randomized, double-blind, placebo controlled study.

SUBJECTS

115 healthy adults

OUTCOMES

Nasal immune response (IL-8), nasal rhinovirus load

UNIVERSITY

University of Virginia, USA; Prof. Ronald B Turner

PUBLICATION

Turner et al.  Beneficial Microbes 2017

http://dx.doi.org/10.3920/BM2016.0160

https://www.ncbi.nlm.nih.gov/pubmed/30061588

Clinical Trial Summary

Strong clinical evidence from community-based study

  • Results showed a significant decrease of 27% in the percentage of URTI episodes in the Bl-04® group vs placebo group (Kang et al., 2013)
  • 0.7 month delay of median time for first respiratory infections compared to the plcebo group
  • Robust long term study completed with a high number of subjects. (310 subjects / 5 months)

 

Unique evidence from the rhinovirus challenge study

  • In the Bl-04® group, less virus was detected in the nasal washes compared to placebo during the infection
  • Decreased proportion of subjects who had a detectable amount of virus
  • A higher concentration of IL-8 after probiotic supplementation, prior to      infection, indicating priming of the immune system
home-office-07-1
*Based on an IQVIA ProVoice® survey of Primary Care Physicians who preferred HOWARU® B. lactis Bl-04® B. lactis Bl-04® for Respiratory Health after review of select clinical studies; December 2018. This claim cannot be used without a trade mark licensing agreement from DuPont or its affiliates.
Immune Health Products
With over 70% of the immune system residing in the digestive tract, our gut is the first line of defense against potentially harmful pathogens and is closely related to overall health. This is why DuPont offers a full range of immune health probiotic options for every stage of life.
csp
Download White Paper

Industry Segment*:

BakeryBarsBeverageConfectioneryCulinaryDairyDietary SupplementsFrozen DessertsFruits ApplicationsPediatric NutritionPet FoodPharmaceuticals

Yes, I would like to receive email communication from DuPont Nutrition & Biosciences. I agree to the Privacy Policy and to DuPont Nutrition & Biosciences getting in contact with me.

Typically, DuPont answers within three working days; queries requiring extensive research may take longer and will be answered as soon as possible.

DuPont cares about your privacy. Your personal information (name, email, phone number and other contact data) will be stored in systems primarily hosted in the United States. This information will be used by DuPont, its affiliates, partners, and selected service providers in other countries to provide you with the product or service information requested. DuPont does not sell your personal information to third parties. To learn more, please visit our Privacy Statement at www.privacy.dupont.com

The system checks that you are in Mainland China. Do you want to switch to the Chinese version?
No
Yes